{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:45:35Z","timestamp":1778654735829,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["SKL-N05"],"award-info":[{"award-number":["SKL-N05"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T07:06:11Z","timestamp":1664089571000},"page":"1356-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy"],"prefix":"10.1016","volume":"44","author":[{"given":"Michael J.","family":"Thorpy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Baldys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haramandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.012_bib0001","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.sleep.2008.05.009","article-title":"Prevalence of narcolepsy in King County, Washington, USA","volume":"10","author":"Longstreth","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0002","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","article-title":"The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study","volume":"25","author":"Silber","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00213-002-1343-4","article-title":"Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies","volume":"167","author":"Thorpy","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0006","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1468-1331.2000.00087.x","article-title":"Problems associated with switch to modafinil - a novel alerting agent in narcolepsy","volume":"7","author":"Guilleminault","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0008","doi-asserted-by":"crossref","first-page":"zsz220","DOI":"10.1093\/sleep\/zsz220","article-title":"Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea","volume":"43","author":"Malhotra","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0009","unstructured":"Sunosi\u2122 (solriamfetol) tablets Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2021."},{"key":"10.1016\/j.clinthera.2022.08.012_bib0010","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi\u00ae (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea [press release]. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-receives-eu-marketing-authorisation-sunosir. Accessed January 21, 2020."},{"key":"10.1016\/j.clinthera.2022.08.012_bib0011","unstructured":"Provigil [package insert]. North Wales, PA: Teva Pharmaceuticals; 2018."},{"key":"10.1016\/j.clinthera.2022.08.012_bib0012","unstructured":"Nuvigil [package insert]. North Wales, PA: Teva Pharmaceuticals; 2018."},{"key":"10.1016\/j.clinthera.2022.08.012_bib0013","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","article-title":"Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial","volume":"199","author":"Schweitzer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0014","doi-asserted-by":"crossref","first-page":"711","DOI":"10.5664\/jcsm.9006","article-title":"Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea","volume":"17","author":"Rosenberg","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0015","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.5664\/jcsm.9328","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline","volume":"17","author":"Maski","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/sleep\/32.11.1425","article-title":"The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents","volume":"32","author":"Gruner","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0017","unstructured":"Wakix [package insert]. Plymouth Meeting, PA: Harmony Biosciences; 2021."},{"key":"10.1016\/j.clinthera.2022.08.012_bib0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.5665\/sleep.2706","article-title":"Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study","volume":"36","author":"Jennum","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101440","article-title":"Cardiovascular disorders in narcolepsy: review of associations and determinants","volume":"58","author":"Jennum","year":"2021","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4088\/JCP.15m10262","article-title":"High rates of psychiatric comorbidity in narcolepsy: findings from the Burden Of Narcolepsy Disease (BOND) study of 9,312 patients in the United States","volume":"78","author":"Ruoff","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0021","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1007\/s12325-022-02249-4","article-title":"Solriamfetol Titration and AdministRaTion (START) in patients with obstructive sleep apnea: a retrospective chart review and hypothetical patient scenario","volume":"39","author":"Singh","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/nop2.191","article-title":"Discourse analysis of health providers' experiences using service design","volume":"6","author":"Eines","year":"2019","journal-title":"Nurs Open"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0023","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","article-title":"A practical guide to the therapy of narcolepsy and hypersomnia syndromes","volume":"9","author":"Mignot","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","article-title":"Comorbidities in a community sample of narcolepsy","volume":"43","author":"Cohen","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14656566.2018.1561861","article-title":"Important decisions in choosing the pharmacotherapy for narcoleptics","volume":"20","author":"de Biase","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2022.08.012_bib0026","unstructured":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2021."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:22:04Z","timestamp":1777490524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002958"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}